Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Inclusion Criteria:

• Type 2 diabetes;
• Serum triglyceride concentration < or = 600 mg/dL;
• Body mass index < or = 37 kg/m2

Exclusion Criteria:

• Type 1 diabetes;
• History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
• Congestive heart failure (NYHA Class III and IV);
• Uncontrolled hypertension;
• Women of Child Bearing Potential
• History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease